Leveraging Digital Technology and Artificial Intelligence to Describe the Real World Belgian Chronic Lymphocytic Leukemia Patient Population [BE-CLLEAR]

03/02/2026
03/02/2026
EU PAS number:
EUPAS1000000394
Study
Finalised
Subscribe
Download as PDF
Study identification

EU PAS number

EUPAS1000000394

Study ID

1000000394

Official title and acronym

Leveraging Digital Technology and Artificial Intelligence to Describe the Real World Belgian Chronic Lymphocytic Leukemia Patient Population [BE-CLLEAR]

DARWIN EU® study

No

Study countries

Belgium

Study description

This multicenter study describes demographics, biomarker testing, and treatment patterns in Belgian patients with chronic lymphocytic leukemia by leveraging natural language processing and the OMOP common data model.

Study status

Finalised
Research institutions and networks

Institutions

AstraZeneca
First published:
01/02/2024
Institution
Universitair Ziekenhuis Antwerpen (UZA)
Belgium
First published:
16/06/2025
Institution Hospital/Clinic/Other health care facility Laboratory/Research/Testing facility ENCePP partner
Algemeen Ziekenhuis Groeninge; Universitair Ziekenhuis Brussel

Contact details

Katoo Muylle 0000-0003-1117-6709

Primary lead investigator
ORCID number:
0000-0003-1117-6709

Study timelines

Date when funding contract was signed

Actual:

Study start date

Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

AstraZeneca BeLux
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable